Bar Harbor BioTechnology | GenomeWeb

Bar Harbor BioTechnology

BRB, which is also developing similar tests for other cancers and autoimmune diseases, has partnered with lab testing services firm Clinical Reference Laboratory for clinical validation of its tests.

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

In an interview with PCR Insider, Greg Shipley, director of the Quantitative Genomics Core Laboratory at University of Texas Health Science Center at Houston, discussed the technique and how UTHSCH researchers are using it.

BHB, founded in 2006, is betting that the new service offering will generate both new revenues and additional sales of its StellARray and XenoQ plate-based PCR kits.

Bar Harbor Biotechnology will offer real-time PCR services to researchers using its StellARrays and XenoQ assays.

Lonza is distributing Bar Harbor BioTechnology's new tools under an exclusive agreement.

Product Watch

Premium

Bar Harbor's XenoQ assays

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.